Adjuvant postoperative accelerated hyperfractionated radiotherapy in rectal cancer: a feasibility study

Details

Serval ID
serval:BIB_6EBFCB233255
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Adjuvant postoperative accelerated hyperfractionated radiotherapy in rectal cancer: a feasibility study
Journal
International Journal of Radiation Oncology, Biology, Physics
Author(s)
Coucke  P. A., Cuttat  J. F., Mirimanoff  R. O.
ISSN
0360-3016 (Print)
Publication state
Published
Issued date
11/1993
Volume
27
Number
4
Pages
885-9
Notes
Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article --- Old month value: Nov 15
Abstract
PURPOSE: To assess the acute toxicity and hence feasibility of postoperative hyperfractionated accelerated radiotherapy in rectal cancer. METHODS AND MATERIALS: Twenty patients were submitted to accelerated hyperfractionated radiotherapy after resection of rectal cancer. A total dose of 48 Gy was given in 3 weeks. Two fractions of 1.6 Gy were used with a mean interfraction interval of at least 6 hours. The pelvic volume was treated by a four-field box technique using a linear accelerator (6-18 MV). Acute toxicity was assessed once per week. Small bowel and skin toxicity were scored according to the criteria of the World Health Organization. Bladder toxicity was scored according to the criteria of the Radiation Therapy Oncology Group. RESULTS: All the patients underwent the treatment as planned except one. No patient presented grade 3 or 4 bladder toxicity. There was only one patient who complained from grade 3 skin toxicity at the end of the treatment. Fourteen patients had some degree of intestinal toxicity. This was the most frequently occurring acute side-effect. Only two out of the fourteen patients had intestinal toxicity exceeding grade 2. CONCLUSION: Hyperfractionated accelerated radiotherapy on a pelvic volume is feasible as far as acute toxicity is concerned.
Keywords
Adenocarcinoma/*radiotherapy/surgery Adult Aged Combined Modality Therapy Feasibility Studies Female Humans Male Middle Aged Postoperative Period Radiotherapy Dosage Radiotherapy, High-Energy/adverse effects Rectal Neoplasms/*radiotherapy/surgery
Pubmed
Web of science
Create date
24/01/2008 17:12
Last modification date
20/08/2019 14:27
Usage data